Arguing that the Food and Drug Administration is “culpable” in creating the opioid crisis, a consumer advocacy group and a leading academic — who also chairs an FDA advisory panel — are calling for the agency to impose a moratorium on approving any new or reformulated opioids.

In a Citizen’s Petition filed with the FDA, Public Citizen and Dr. Raeford Brown, a professor of anesthesiology and pediatrics at the University of Kentucky, maintained the agency has displayed “dangerously deficient oversight” and that none of more than two dozen opioids approved between 2009 and 2015 provided benefits that outweighed the risks. Two drugs — Opana ER and Dsuvia — were singled out as examples.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • what are the documented instances of diversion of Dsuvia? Lack of retail distribution almost certainly makes this very rare because it is so much more difficult to obtain.
    As you note, Opana ER was approved in 2006, which is outside of the 2009-2015 timeframe discussed here. And it wasn’t designated “abuse deterrent” because that approval predates FDA guidance on what that would be and how it would be determined. It’s like saying a person didn’t travel by auto before autos were invented.
    Not that facts matter anymore in the Rx opioid conversation (unless they fit the current narrative).

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy